Gaucher Disease: A Glance from a Medicinal Chemistry Perspective

Herein we consider the Gaucher disease (GD) from a medicinal chemistry perspective. GD presents three clinical forms, one that can be successfully treated by recombinant enzymes, and two not responding to enzyme replace therapy. The use of small molecules able to inhibit the glucosylceramide synthase, target for the substrate reduction therapy, is scarcely successful because many of them are not able to efficiently reach the central nervous system.

Abstract

Rare diseases are particular pathological conditions affecting a limited number of people and few drugs are known to be effective as therapeutic treatment. Gaucher disease, caused by a deficiency of the lysosomal enzyme glucocerebrosidase, belongs to this class of disorders, and it is considered the most common among the Lysosomal Storage Diseases. The two main therapeutic approaches are the Enzyme Replacement Therapy (ERT) and the Substrate Reduction Therapy (SRT). ERT, consisting in replacing the defective enzyme by administering a recombinant enzyme, is effective in alleviating the visceral symptoms, hallmarks of the most common subtype of the disease whereas it has no effects when symptoms involve CNS, since the recombinant protein is unable to significantly cross the Blood Brain Barrier. The SRT strategy involves inhibiting glucosylceramide synthase (GCS), the enzyme responsible for the production of the associated storage molecule. The rational design of new inhibitors of GCS has been hampered by the lack of either the crystal structure of the enzyme or an in-silico model of the active site which could provide important information regarding the interactions of potential inhibitors with the target, but, despite this, interesting results have been obtained and are herein reviewed.

Zum Volltext